GENTAUR Molecular Products.
Monoclonal Antibody, ELISA Kit, Polyclonal Antibody, Recombinant/Purified Protein.
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, sales@genprice.com
Index / Biovis / Daunorubicin.HCl / Product Detail : 1524-500 Daunorubicin.HCl
Related keywords:
Jul
23th
#1524-500 Daunorubicin.HCl
| Price : | 1554 | EUR |
| 1764 | USD | |
| 1205 | GBP | |
| 6529 | Zloty | |
| 207982 | JPY | |
| 11987 | NOK | |
| 12844 | SEK | |
| 1758 | CHF |
Product name : Daunorubicin.HCl
Catalog number : 1524-500
Quantity: 500 mg
Availability: Yes
Supplier name : Biovis
Data sheet: Ask more or other datasheet now !
More Details about
Alternate Name/Synonyms: Daunomycin hydrochloride
Appearance: Orange-red powder
Formulation: N/A
CAS Number: 23541-50-6
Molecular Formula: C₂₇H₂₉NO₁₀ · HCl
Molecular Weight: 563.98
Purity: >95%
Solubility: H₂O or MeOH
Storage Temp.: -20°C
Shipping Conditions: RT
Description: Potent anti-cancer agent whose potential target site may be mitochondrial cytochrome c oxidase. Inhibits RNA and DNA synthesis. Also inhibits eukaryotic topoisomerase I & II. Induces DNA single strand breaks and apoptosis in HeLaS3 tumor cells.
Handling: Protect from moisture
USAGE: For Research Use Only! Not For Use in Humans.
Contact us about this product :
Our team will respond you as soon as possible !
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com | Gentaur
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
RCS Paris B 484 237 888
SIRET 48423788800017
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
france@gentaur.com | Gentaur
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur
GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel: 0208-080893 Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62 SWIFT RABONL2U
GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur
ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX 058 710 33 48
poland@gentaur.com | Gentaur
Other countries
Österreich +43720880899
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Danmark +4569918806
Finland Helsset +358942419041
Magyarország Budapest +3619980547
Ireland Dublin+35316526556
Luxembourg+35220880274
Norge Oslo+4721031366
Sverige Stockholm+46852503438
Schweiz Züri+41435006251
US New York+17185132983
GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur
Related products : Daunorubicin.HCl
Gentaurpub
WP1025: B Cell Receptor Signaling Pathway
WP1087: IL-5 Signaling Pathway
WP1144: B Cell Receptor Signaling Pathway
WP1315: IL-5 Signaling Pathway
WP1354: B Cell Receptor Signaling Pathway
WP151: IL-5 Signaling Pathway
WP2272: Pathogenic Escherichia coli infection
WP274: B Cell Receptor Signaling Pathway
WP285: B Cell Receptor Signaling Pathway
WP44: IL-5 Signaling Pathway
WP744: IL-5 Signaling Pathway
WP794: B Cell Receptor Signaling Pathway
WP849: IL-5 Signaling Pathway
WP908: B Cell Receptor Signaling Pathway
WP968: IL-5 Signaling Pathway
Related Genes :
[LYK3 HCL RLK3 MTR_5g086130] LysM domain receptor-like kinase 3 (LysM-containing receptor-like kinase 3) (MtLYK3) (EC 2.7.11.1) (LysM receptor kinase K1B) (Protein HAIR CURLING)
[COLEC12 CLP1 NSR2 SCARA4 SRCL] Collectin-12 (Collectin placenta protein 1) (CL-P1) (hCL-P1) (Nurse cell scavenger receptor 2) (Scavenger receptor class A member 4) (Scavenger receptor with C-type lectin)
[AKR1B1 ALDR1] Aldose reductase (AR) (EC 1.1.1.21) (Aldehyde reductase) (Aldo-keto reductase family 1 member B1)
[] HERV-H_2q24.3 provirus ancestral Env polyprotein (Env protein HERV-H/p62) (Env protein HERV-H19) (Env protein HERV-Hcl.3) (Envelope polyprotein) (HERV-H/env62) [Cleaved into: Surface protein (SU); Transmembrane protein (TM)]
[doxA] Cytochrome P-450 monooxygenase DoxA (EC 1.14.13.181) (13-deoxycarminomycin C-13 hydroxylase) (13-deoxydaunorubicin C-13 hydroxylase) (13-dihydrocarminomycin C-13 hydroxylase) (13-dihydrodaunorubicin C-13 hydroxylase) (Daunorubicin C-14 hydroxylase)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[hcl] 3-hydroxybenzoate--CoA/4-hydroxybenzoate--CoA ligase (EC 6.2.1.27) (EC 6.2.1.37) (3-hydroxybenzoyl-CoA synthetase)
[AW171_hschr31970] HCL051Cp
[cytb] Cytochrome b
[ABCB4 MDR3 PGY3] Phosphatidylcholine translocator ABCB4 (ATP-binding cassette sub-family B member 4) (Multidrug resistance protein 3) (EC 3.6.3.44) (P-glycoprotein 3)
[drrA] Daunorubicin/doxorubicin resistance ATP-binding protein DrrA (EC 3.6.3.-)
[ABCG2 ABCP BCRP BCRP1 MXR] ATP-binding cassette sub-family G member 2 (Breast cancer resistance protein) (CDw338) (Mitoxantrone resistance-associated protein) (Placenta-specific ATP-binding cassette transporter) (Urate exporter) (CD antigen CD338)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
[COI] Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Fragment)
Bibliography :
[28728917] Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.
[28711923] Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.
[28665351] Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
[28655097] [Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia].
[28653879] TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC.
[28648578] Application of aptamers in treatment and diagnosis of leukemia.
[28647120] DrrC protein of Streptomyces peucetius removes daunorubicin from intercalated dnrI promoter.
[28645262] Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature.
[28644114] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
[28643323] Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Share this page:
Enter catalog number :
Favorites Pages:
No Favorits